CNTA Centessa Pharmaceuticals plc

Nasdaq centessa.com


$ 23.69 $ 0.17 (0.72 %)    

Tuesday, 04-Nov-2025 13:13:10 EST
QQQ $ 620.91 $ -2.34 (-0.38 %)
DIA $ 470.72 $ 0.36 (0.08 %)
SPY $ 675.62 $ -0.51 (-0.08 %)
TLT $ 89.94 $ 0.15 (0.17 %)
GLD $ 363.41 $ -0.06 (-0.02 %)
$ 23.94
$ 23.53
$ 23.66 x 101
$ 23.72 x 6
$ 23.58 - $ 24.07
$ 9.60 - $ 25.42
904,630
na
3.2B
$ 0.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stephens--co-initiates-coverage-on-centessa-pharmaceuticals-with-overweight-rating-announces-price-target-of-35

Stephens & Co. analyst Sudan Loganathan initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight r...

 guggenheim-reiterates-buy-on-centessa-pharmaceuticals-maintains-28-price-target

Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price...

 3-biotech-stocks-showing-strength-with-big-spikes-in-momentum-scores

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

 wells-fargo-initiates-coverage-on-centessa-pharmaceuticals-with-overweight-rating-announces-price-target-of-31

Wells Fargo analyst Benjamin Burnett initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating a...

 chardan-capital-maintains-buy-on-centessa-pharmaceuticals-maintains-30-price-target

Chardan Capital analyst Rudy Li maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $30 price target.

 centessa-pharmaceuticals-q2-eps-038-misses-034-estimate

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which missed the analyst consensus estima...

 chardan-capital-maintains-buy-on-centessa-pharmaceuticals-maintains-30-price-target

Chardan Capital analyst Rudy Li maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $30 price target.

 truist-securities-initiates-coverage-on-centessa-pharmaceuticals-with-buy-rating-announces-price-target-of-30

Truist Securities analyst Danielle Brill initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and ...

 needham-initiates-coverage-on-centessa-pharmaceuticals-with-buy-rating-announces-price-target-of-35

Needham analyst Ami Fadia initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price...

 centessa-pharmaceuticals-q1-eps-020-beats-037-estimate-sales-1500m

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate...

 chardan-capital-initiates-coverage-on-centessa-pharmaceuticals-with-buy-rating-announces-price-target-of-30

Chardan Capital analyst Rudy Li initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces...

 piper-sandler-initiates-coverage-on-centessa-pharmaceuticals-with-overweight-rating-announces-price-target-of-38

Piper Sandler analyst Biren Amin initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and a...

 guggenheim-reiterates-buy-on-centessa-pharmaceuticals-maintains-28-price-target

Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price...

 morgan-stanley-assumes-centessa-pharmaceuticals-at-overweight-maintains-price-target-of-27

Morgan Stanley analyst Jeffrey Hung assumes Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and maintains Pr...

 centessa-pharmaceuticals-announces-poster-presentation-of-phase-1-clinical-data-for-orx750-a-novel-orexin-receptor-2-agonist-at-the-aan-2025-annual-meeting

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION